Price T Rowe Associates Inc Eye Point Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,354,014 shares of EYPT stock, worth $14.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,354,014
Previous 2,144,747
36.87%
Holding current value
$14.1 Million
Previous $16 Million
54.07%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding EYPT
# of Institutions
167Shares Held
71.7MCall Options Held
232KPut Options Held
207K-
Cormorant Asset Management, LP Boston, MA8.33MShares$87 Million4.79% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.8MShares$71.1 Million1.61% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.2MShares$64.8 Million0.07% of portfolio
-
Franklin Resources Inc San Mateo, CA4.15MShares$43.4 Million0.01% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.09MShares$42.7 Million0.05% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $356M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...